Mission Cancer + Blood

Clinical Trials

Breast HER2- ELEGANT

Study #ELEGANT

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

Description
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Sponsor: Stemline Therapeutics, Inc.

Principal Investigator: Dr. Seema Harichand

Interested in this trial? Email [email protected].

 

Back To Clinical Trials NCI Database Entry